GENIL Analyst Meeting Notes
Tacirler Investment
In our analyst meeting with Gen İlaç management, we discussed recent developments in the company’s ongoing operations, regulatory actions taken to date, R&D projects expected to support medium to long term growth, and the company’s overall growth strategy. The key takeaway from the meeting was that Gen İlaç continues to preserve its strong cash generating business model in the short term, while steadily advancing its transformation into an R&D and manufacturing focused biotechnology company over the medium and long term.